Why did United Therapeutics complete its $2 billion authorization now?

According to CEO Martine Rothblatt, the company believes the market is not yet reflecting the scale of United Therapeutics' potential, citing multiple growth drivers approaching inflection points beginning as soon as next year. The company views share repurchase as a disciplined capital allocation decision that allows it to invest in its own future while rewarding shareholders.

What is an Accelerated Share Repurchase (ASR) agreement?

An ASR is a structured buyback mechanism where a company pays an investment bank upfront and receives an initial delivery of shares immediately (typically 75% of the total anticipated repurchase), with final settlement based on the volume-weighted average price over the contract period. This allows companies to retire shares faster than open-market purchases.

How much has United Therapeutics returned to shareholders through buybacks?

Upon completion of this $477.6 million final ASR, United Therapeutics will have returned approximately $4 billion to shareholders in approximately 2.5 years, comprised of $1.5 billion in prior ASR agreements (March 2026), $22.4 million in open-market purchases (Q3 2026), and the current $477.6 million ASR.

Could United Therapeutics have to pay cash to Citibank at settlement?

Yes. While United Therapeutics may receive additional shares at final settlement, the agreement terms allow that in certain limited circumstances, the company could be required to make a cash payment to Citibank, or alternatively deliver shares to Citibank if the company elects to do so, depending on final pricing.

UTHR 8-K Filed 2026-09-08 Execution disclosure

United Therapeutics enters $477.6M ASR to complete $2B buyback

Final tranche of previously announced authorization deployed via accelerated share repurchase with Citibank, expected to close in Q4 2026.

MechanismAccelerated Share Repurchase

What the filing says

United Therapeutics Corporation announced on September 8, 2026, that it will enter into an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A. to repurchase approximately $477.6 million of its common stock, representing the remainder of its previously announced $2.0 billion share repurchase authorization.

Under the ASR agreement, United Therapeutics will make an aggregate upfront payment of approximately $477.6 million on or around September 10, 2026, and will receive an initial delivery of shares representing approximately 75% of the total shares anticipated to be repurchased based on the closing stock price on September 8, 2026. The final number of shares repurchased will be determined based on the average of daily volume-weighted average prices during the ASR term, less a discount and subject to agreement adjustments. Final settlement is expected in the fourth quarter of 2026.

The company has previously deployed $1.5 billion of the $2 billion authorization through ASR agreements executed in March 2026, and purchased an additional $22.4 million in open-market transactions during Q3 2026. Upon completion of this final $477.6 million repurchase, United Therapeutics will have returned approximately $4 billion to shareholders in approximately 2.5 years. As of September 4, 2026, the company had approximately 42.9 million shares outstanding.

United Therapeutics today will enter into an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A. to repurchase the company's common stock, for approximately $477.6 million. The company previously entered into ASR agreements to repurchase an aggregate $1.5 billion of its common stock in March 2026, and purchased an additional $22.4 million of its common stock in open-market transactions during the third quarter of 2026. — UNITED THERAPEUTICS Corp 8-K filing · View on SEC EDGAR →

What this means

This filing marks the final tranche execution of United Therapeutics' $2 billion share repurchase authorization announced earlier. The $477.6 million ASR with Citibank completes the deployment of the full authorization, with the company having previously used $1.5 billion in ASR agreements (March 2026) and $22.4 million in open-market purchases (Q3 2026). Over approximately 2.5 years, the company will have returned $4 billion to shareholders through repurchases. The ASR mechanism allows the company to receive 75% of anticipated shares upfront, with final settlement in Q4 2026 based on volume-weighted average pricing. With 42.9 million shares outstanding as of early September 2026, the cumulative buyback represents a meaningful reduction in share count, though specific per-share impact depends on final ASR settlement pricing.

Frequently asked questions

Why did United Therapeutics complete its $2 billion authorization now?: According to CEO Martine Rothblatt, the company believes the market is not yet reflecting the scale of United Therapeutics' potential, citing multiple growth drivers approaching inflection points beginning as soon as next year. The company views share repurchase as a disciplined capital allocation decision that allows it to invest in its own future while rewarding shareholders.
What is an Accelerated Share Repurchase (ASR) agreement?: An ASR is a structured buyback mechanism where a company pays an investment bank upfront and receives an initial delivery of shares immediately (typically 75% of the total anticipated repurchase), with final settlement based on the volume-weighted average price over the contract period. This allows companies to retire shares faster than open-market purchases.
How much has United Therapeutics returned to shareholders through buybacks?: Upon completion of this $477.6 million final ASR, United Therapeutics will have returned approximately $4 billion to shareholders in approximately 2.5 years, comprised of $1.5 billion in prior ASR agreements (March 2026), $22.4 million in open-market purchases (Q3 2026), and the current $477.6 million ASR.
When will the final settlement of this ASR occur?: The final settlement of the ASR agreement is expected to be completed in the fourth quarter of 2026. The company will make the upfront payment of approximately $477.6 million on or around September 10, 2026, with settlement timing and final share count determined by volume-weighted average pricing and agreement terms.
What share count should investors expect after this buyback?: The filing does not specify the exact number of shares to be repurchased, as final count depends on average pricing during the ASR term. As of September 4, 2026, the company had approximately 42.9 million shares outstanding; the share count will decline by the number of shares ultimately repurchased at final settlement.
Could United Therapeutics have to pay cash to Citibank at settlement?: Yes. While United Therapeutics may receive additional shares at final settlement, the agreement terms allow that in certain limited circumstances, the company could be required to make a cash payment to Citibank, or alternatively deliver shares to Citibank if the company elects to do so, depending on final pricing.

execution asr accelerated-share-repurchase biotech uthr

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.